Chapter 83: Antiviral Agents II: Drugs for HIV Infection

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Imagine fighting an enemy that changes its disguise,

its weapons, and its tactics up to 10 billion times every single day.

If you throw your absolute best weapon at it, it just adapts, mutates, and keeps coming.

That is the reality of trying to manage HIV.

It is, yeah.

It's the ultimate moving target.

The sheer speed of replication and mutation makes it one of the most complex clinical challenges in modern medicine.

Absolutely.

They're not just treating a static infection.

You are trying to outsmart an incredibly relentless evolutionary engine.

Which is exactly why we are dedicating this deep dive tailored specifically for you as a clinician and a student.

Yeah, we're glad you're here.

Our mission today is to act as your ultimate one -on -one tutor from the Last Minute Lecture team.

We are going to break down the heavy pharmacotherapeutics of HIV management from Chapter 83 of Lens.

We're talking the underlying path of physiology, how that dictates our drug selection,

the massive drug interactions, and really how to keep your patients safe.

And this clinical focus is non -negotiable.

Even if infectious disease isn't your primary specialty,

you are going to see patients taking these antiretroviral regimens alongside medications for blood pressure or diabetes or depression.

Yeah, they don't exist in a vacuum.

Exactly.

Because of the intense black box warnings and drug interactions, you have to know exactly how these medications collide.

Because if you don't, the results can be fatal.

So as a clinician, you need a battle plan.

I like to think of our approach today like a tactical briefing.

I like that.

Before we can start throwing the eight classes of antiretroviral drugs at the patient, we have to study the enemy's tactics.

We have to know the blueprint.

Right.

We have to know exactly how HIV hijacks the human body.

So let's start there.

What makes this virus so uniquely devastating?

It all comes down to its classification.

HIV is a retrovirus.

Now, in a normal human cell, the flow of genetic information is DNA to RNA to protein.

That's the standard operating procedure.

Yeah, exactly.

But HIV carries single -stranded RNA as its genetic material.

So to take over a human cell, it has to work backwards.

Oh, wow.

Yeah, it has to force its RNA to be rewritten into DNA.

And to do this, it brings along its own specialized enzyme called reverse transcriptase.

Right.

And it doesn't just attack any random cell.

It is incredibly specific.

Highly targeted.

It hones in on CD4 T cells, our helper T lymphocytes, which are basically the generals that orchestrate the entire immune system.

Right.

HIV physically attaches to the CD4 proteins on the surface of these cells.

But here's the part that makes eradication so difficult.

It also infects macrophages and microglial cells in the central nervous system.

That is a critical distinction to make.

An infected CD4 T cell usually dies in about a day and a half.

But those macrophages...

They don't die, right?

They don't die.

They act like sleeper cells.

They serve as this chronic long -term reservoir for the virus, hiding it from both the immune system and our drugs.

So let's look at the actual heist.

How does a single viral particle, a virion, break in and take over?

Well, if we map out its replication cycle from the text, it's essentially a 10 -step blueprint that we were trying to sabotage.

OK, so step one.

It starts with attachment fusion.

The virus has these proteins on its envelope, specifically GP120 and GP41, which act like a lockpick.

Got it.

So GP120 binds to the CD4 receptor, but it also needs a co -receptor, usually one called CCR5, to really tighten the grip.

And once it's locked on, the viral envelope literally melts into the host cell membrane.

Exactly.

Once inside, it unpacks its RNA and gets to work.

This is where that reverse transcriptase enzyme comes in.

Think of it as a hasty translator working in the dark.

A hasty translator.

I like that.

It reads the single -stranded viral RNA and translates it into double -stranded DNA.

Then we have integration.

The virus uses another enzyme, aptly named integrase.

This is the inside man.

Integrase takes that newly minted viral DNA, carries it into the host cell's nucleus, and splices it directly into the human DNA.

From that moment on, the host cell is permanently infected.

It's tricked into reading that viral code and just manufacturing raw viral proteins.

Right.

And then the cell assembles these new proteins and buds off from the host.

But there's a final crucial step, which is maturation.

This is step 10.

Right.

When the new virus buds off, it's actually immature and totally harmless.

It requires a viral enzyme called protease, which acts like a pair of chemical scissors.

Exactly.

Protease chops up the large, clunky proteins into functional, active pieces.

If those scissors don't work, the virus can't infect other cells.

Okay, I want to circle back to something you said about reverse transcriptase, the hasty translator working in the dark.

The text mentions a staggering replication rate,

billions of variants a day.

Billions.

If it's replicating that fast and the translator's hasty, isn't it making massive errors?

Why isn't the virus just mutating itself into extinction?

You'd think so, right.

But that sloppiness is actually its greatest superpower.

Reverse transcriptase is an incredibly aeroprone enzyme.

Oh, interesting.

It introduces incorrect bases into the DNA constantly.

Most of those mutations are probably useless, but out of billions,

a few will randomly change the shape of the virus just enough that our drugs can no longer bind to it.

So it's basically stumbling into drug resistance purely by the sheer volume of mistakes it makes.

Exactly.

And that rapid mutation directly dictates our entire therapeutic strategy.

Because if you use one drug.

Right.

If you try to fight HIV with just one drug, you are actively selecting for the mutant strains that survive.

Within weeks, the entire viral population will be resistant.

Wow.

That is why we must use combination therapy, antiretroviral therapy, or RT.

We have to hit multiple steps of that replication cycle simultaneously.

So before we dive into that multi -drug arsenal, what does this actually look like in the patient?

Because as a provider, you're not seeing the cellular level, you know.

You're seeing the clinical presentation.

Right.

And the clinical course happens in three distinct phases.

The initial phase is when the virus first enters the body.

There's massive viral replication.

The immune system hasn't figured out what's happening yet.

So viral loads can just explode over 10 million copies per milliliter of blood.

And this triggers acute retroviral syndrome.

Yes.

Box 83 .1 in the text lists this out.

It usually presents with fever, swollen lymph nodes, sore throat, and a rash.

It looks and feels exactly like a bad case of the flu or mononucleosis.

Exactly.

And because of that, it goes completely unrecognized by the vast majority of patients and providers.

That's terrifying.

It is.

After the immune system finally mounts a defense, the viral load drops and we enter the middle phase, which is clinical latency.

So they feel fine.

The patient might feel totally fine, yeah, and this phase can last roughly 10 years.

But it's not a truce.

Beneath the surface, the virus is relentlessly replicating and the CD4 T cells are progressively dying off.

Which brings us to the late phase AIDS.

The immune generals, the CD4 cells, drop below 200 cells per cubic millimeter.

The immune system collapses, leaving the patient completely vulnerable to opportunistic infections and central nerve system complications.

To prevent that collapse, clinicians rely on our antiretroviral arsenal.

We can group the eight drug classes into two broad strategies from table 83 .1.

Let's break that down.

We have drugs that block viral entry from the outside and drugs that inhibit the viral enzymes on the inside.

Let's start with the inside job.

We are going to sabotage the virus at the reverse transcription phase.

Our first class is the NRTIs, the nucleoside or nucleotide reverse transcriptase inhibitors.

That's a mouthful.

It really is.

These are the oldest class and they are essentially pro drugs, meaning they only become active once the host cell modifies them.

Their mechanism is brilliant, really.

Remember the hasty translator building a DNA strand?

NRTIs act as faulty building blocks.

When reverse transcriptase reaches for a structural piece to add to the DNA chain, it accidentally grabs the NRTI.

And because it's defective.

Because the NRTI is chemically defective, it lacks the attachment point for the next block the DNA chain abruptly terminates.

The virus is stuck with half a blueprint.

The classic prototype here is abacavir, but the adverse effects are intense.

Very intense.

Because these drugs are fake building blocks, the virus isn't the only thing that gets tricked.

Our own mitochondria,

the powerhouses of our cells, use similar machinery to build their own DNA.

Yes, and that leads to severe mitochondrial toxicity.

The mitochondria start failing, which causes a buildup of lactic acid in the blood.

Known as lactic acidosis.

Right.

It also severely impacts the liver, leading to hepatomegaly with steatosis, which is a dangerously enlarged fatty liver.

And there's a massive specific safety alert for abacavir that every clinician must memorize.

Oh, it's a little critical.

Up to 8 % of patients will develop a severe, life -threatening hypersensitivity reaction.

It can cause multi -organ failure.

So before you ever write a prescription for abacavir, you absolutely must screen the patient for a specific genetic variation called HLAB5701.

If they test positive for that gene, they can never, ever receive this drug.

It is a hard, non -negotiable rule in the guidelines.

Now, let's contrast the NRTIs with their sibling class.

The NNRTIs, the non -nucleoside reverse transcriptase inhibitors.

They target the exact same enzyme, right?

They do, but their approach is entirely different.

They aren't fake building blocks, they are direct inhibitors.

Oh, I see.

They bind right to the active center of the reverse transcriptase enzyme and force a physical structural change that just ruins its ability to function.

Okay, so the prototype NNRTI is efavirenz.

Now wait,

I have to challenge something here.

Okay, go for it.

We look at the adverse effects for efavirenz in the text, and they are wild.

Over half of patients experience central nervous system issues, dizziness, insomnia, vivid nightmares, even delusions and hallucinations.

Yeah, the CNS effects are very common.

And it can also cause severe life -threatening rashes like Stevens -Johnson syndrome, and it is highly teratogenic, meaning it can cause severe birth defects.

Yes, it is.

If a drug causes psychiatric symptoms in 50 % of people and harms fetal development,

why on earth is it considered a front -line prototype?

That sounds like a cure that's almost as bad as the disease.

It's a fantastic question, and it highlights the constant risk versus reward calculation you do in clinical pharmacology.

Why do we tolerate those side effects?

Right, why?

Because efavirenz has a unique advantage.

It easily crosses the blood -brain barrier.

Oh.

Remember those macrophage sleeper cells hiding in the central nervous system?

Efavirenz can reach them.

It drives down viral loads in those hard -to -reach sanctuary sites better than many other drugs.

So it's a necessary evil.

In a way.

And clinically, we know that those severe CNS symptoms typically resolve on their own after two to four weeks as the body adjusts.

You educate the patient to take it at bedtime on an empty stomach to minimize the peak concentrations in the brain while they're actually awake.

Okay, that makes a lot of sense.

You're trading a rough adjustment period for access to the VIP areas where the virus hides.

Exactly.

So we've tried to stop the DNA translation, but what if the virus slips past?

We need a backup plan.

Where else in the replication cycle can we strike?

We can go to the very end of the line step 10.

If the virus manages to copy its DNA, integrate it, and bud off the cell, we can still stop it from becoming infectious by blocking those chemical fizzers.

The protease inhibitors, or PIs, if we block the protease enzyme, the virus buzz off as a clunky, immature, non -infectious blob.

Derunavir is our prototype here, and it's powerful because it works even against strains that have mutated to resist older PIs.

But the metabolic toll these drugs take on a patient's body is profound.

It really is.

Protease inhibitors can cause severe hyperglycemia, leading to new -onset diabetes.

They cause profound hypolipidemia, just skyrocketing cholesterol and triglycerides.

Wow.

Then there's lepidistrophy.

Right, the fat redistribution.

Patients develop this pseudo -cushing appearance.

Yeah, it's very distinct.

The fat drains out of their face and extremities, making them look hollowed out, and it massively accumulates in their abdomen and at the base of their neck.

It's a huge body image issue for patients.

On top of that, you have to monitor for elevated liver transaminases, decreased cardiac conduction velocity, and increased bleeding, especially if the patient has hemophilia.

It is a heavy systemic burden.

And pharmacologically, protease inhibitors are notorious for drug interactions because they heavily inhibit the cytochrome P450 enzyme system in the liver.

Okay, I love the pharmacology hack that clinicians use for this, though.

Let's talk about the CYP450 system.

Let's do it.

Picture that enzyme system in the liver as a massive high -speed traffic intersection.

All the drugs your patient takes have to pass through this intersection to be metabolized and cleared from the body.

Right.

Usually, if a drug inhibits those enzymes, it's dangerous.

It causes a traffic jam, and other drugs build up to toxic levels.

But with HIV treatment, clinicians cause a planned traffic jam.

Exactly.

It's called ritonavir boosting.

Right.

Ritonavir is actually an older protease inhibitor, but it's exceptionally good at blocking the CYP450 enzymes.

Almost too good.

So clinicians will prescribe a tiny subtherapeutic dose of ritonavir alongside the main drug, like darunavir.

The ritonavir drives into the intersection and completely clogs up the enzymes.

Yeah, just shuts down the intersection.

While the liver is busy dealing with the ritonavir traffic jam, the darunavir sneaks right past, avoids being broken down, and stays in the bloodstream at higher therapeutic levels for a much longer time.

It's a perfect example of leveraging a drug interaction to our advantage.

It means the patient can take fewer pills less often with better viral suppression.

That's brilliant.

Now, let's step back slightly in the viral cycle.

What if we want to stop the inside man, the enzyme that splices the viral DNA into the human chromosome?

That would be the integrase strand transfer inhibitors, or NSTIs.

If the viral DNA can't integrate, the host cell never gets the blueprint and replication stops cold.

Our prototype here is raltogravir.

It is highly effective and is actually a first -choice drug for treatment -naive patients, people just starting therapy.

And it's better tolerated, right?

Much better.

From a clinical perspective, it is much better tolerated than the proteus inhibitors.

The adverse effects are generally minor, like dizziness or insomnia.

But as a clinician, you can't get complacent, you still have to monitor them.

Always.

Raltogravicaria is a rare but fatal risk of Stevens -Johnson syndrome, and you have to watch their labs for elevated liver enzymes and CK creatine kinase elevation, which is a red flag for dangerous muscle breakdown or rhabdomyolysis.

Precisely.

Now, everything we've discussed so far happens inside the cell, but what if we blockade the door?

Right, keep it out entirely.

What if we stop the virus from ever getting inside the CD4 cell in the first place?

Let's look at the entry inhibitors.

First, we have the fusion inhibitors.

The prototype is infuvertide, often referred to as T20.

It binds directly to the viral GP41 protein, the lockpick on the outside of the virus, and physically prevents the viral envelope from melting into the host cell.

But this isn't a frontline drug.

It's reserved for HIV strains that are resistant to everything else.

And when you look at the administration, you see why.

Right.

It's a large peptide, so it can't be taken as a pill, stomach acid would just destroy it.

Makes sense.

So it requires a subcutaneous injection twice a day.

And the clinical reality is brutal.

98 % of patients experience severe injection site reactions.

Wait, 98 %?

Yeah.

Almost everyone.

We're talking pain, nodules, and cysts at the injection site.

It also carries an increased risk of bacterial pneumonia.

That sounds incredibly rough for a twice -daily injection.

Next up, we have the CCR5 antagonist, Muraviroc.

This one takes a different approach.

It does.

Instead of binding to the virus, it binds to the host cell's CCR5 coreceptor.

It basically changes the locks on the door so the virus can't grab hold.

Right.

But if you're a clinician prescribing this, there is a critical molecular background check you have to perform first.

Yes.

You must run a highly sensitive tropism assay.

A tropism assay.

Right.

HIV is tricky.

While most strains use the CCR5 doorway to get in, some mutated strains use a different doorway called CXCR4.

Oh, I see.

So a tropism assay tests the patient's specific viral strain to prove it, relies on CCR5.

If the virus uses the other doorway, Muraviroc will be completely useless.

That's a vital step.

It is.

You also have to closely monitor the patient's liver, as it can cause severe hepatotoxicity, which is often preceded by a systemic allergic reaction like a rash.

We also have newer classes for multidrug -resistant HIV.

There's Phostum savir, an attachment inhibitor, and Abolizumab, a post -attachment inhibitor.

Yes, the newest lines of defense.

But the one that really feels like science fiction from the text is the new capsid inhibitor, Lanocapivir.

It disrupts the protein shell of the virus.

But what makes it a pharmacokinetic marvel is the dosing.

It is a staggering advancement.

Because of how it's formulated and absorbed, Lanocapivir is administered as a subcutaneous injection just once every six months.

Think about that leap.

From injecting in fuvertide twice a day and dealing with painful cysts, to getting one shot of Lanocapivir twice a year.

It's incredible.

It entirely changes the landscape of patient adherence.

It does.

But having this incredible arsenal of drugs is only half the battle.

As a clinician, you have to know how to deploy them, how to measure success, and really how to protect the public.

So let's talk labs.

When you're managing an HIV patient, your two core metrics are the viral load and the CD4 T -cell count.

From box 83 .2, yes.

Think of the viral load which measures plasma HIV RNA as the speedometer.

It tells you the magnitude of replication, how fast the engine is running.

Your therapeutic goal is to drive that number down so low that it is clinically undetectable.

And then you have the CD4 count, which tells you how much damage the chassis has already taken.

It indicates the current strength of the immune system.

So a rising CD4 count is good.

Yes, a rising CD4 count means the immune system is recovering.

But those aren't the only labs you run.

Because of the massive metabolic toll of these drugs, you are constantly pulling liver panels, kidney function tests, and lipid panels.

Right, to monitor for that hepatotoxicity, lactic acidosis, and hyperlipidemia we talked about.

Exactly.

You're treating the whole patient, not just the virus.

Patient education is just as critical as the labs.

You have to hammer home the importance of adherence.

It's everything.

If a patient misses doses, the drug levels drop, the virus starts replicating again, And because of that sloppy reverse transcriptase, it mutates and develops resistance to the entire regimen.

Yeah, you lose the drugs.

You also have to educate them that even if their viral load is undetectable, they must still avoid transmission behaviors.

Which leads us to the final piece of the puzzle prophylaxis.

How do we protect the uninfected?

Pre -EP and P.

Right.

We use pre -EP, or pre -exposure prophylaxis, for high -risk HIV -negative individuals.

The standard protocol is a daily combination pill of tenafovir and imtricidabine.

But it requires strict oversight.

Highly strict.

You give the patient a 90 -day supply, and before you refill it, you bring them back for rigorous HIV testing to ensure they haven't contracted the virus.

And then there's PP, post -exposure prophylaxis.

This is the emergency protocol.

It could be occupational, like a nurse getting a needle stick injury, or non -occupational, like unprotected sex.

The single most important factor here is the ticking clock.

Timing is absolutely everything.

You have to start the multi -drug regimen within one to two hours of exposure.

Wow, that fast.

Yes.

If you wait past 72 hours, the window is closed.

The virus has likely established that permanent macrophage reservoir, and the patient must stay on that aggressive regimen for a full 28 days.

It's intense, but it is our best shot at helping the immune system clear the virus before it digs in.

It is.

So, left the back and look at the big picture.

As a clinician, understanding the exact microscopic pathophysiology of HIV, how it translates its RNA, how it splices its code, how it cuts its proteins, isn't just academic trivia.

Not at all.

It is the very foundation of your treatment strategy.

It allows you to strategically deploy these eight drug classes to blockade, sabotage, and corner the virus.

Exactly.

By combining these mechanisms and managing the inevitable side effects and drug interactions, we have turned to what was once a universally fatal infection into a highly manageable chronic disease.

It truly is a triumph of modern pharmacology.

We want to extend a warm thank you to you on behalf of the Last Minute Lecture team for diving into this incredibly complex, high -stakes material with us today.

It's been great.

And to leave you with one final thought to mull over.

We started this deep dive talking about a relentless enemy replicating billions of times a day, right?

Yeah.

Demanding an equally relentless daily regimen of multi -drug pills that constantly remind the patient of their disease.

But with the advent of capsid inhibitors like lenacapivir, dose just once every six months,

are we on the precipice of a world where the daily psychological burden of HIV is entirely erased by pharmacology?

And if we can achieve perfect adherence through twice a year dosing, what does that mean for

actually eradicating this disease once and for all?

It makes you wonder.

The blueprint of this virus has been shifting and adapting for decades.

But maybe, finally, we're the ones drawing the plans.

Catch you on the next deep dive.